首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1534259

全球出血性疾病治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Bleeding Disorder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 131 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球出血性疾病治疗市场需求预计将从 2023 年的 162.9 亿美元达到 2032 年近 343.9 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 8.66%。

出血性疾病治疗包括一系列治疗介入措施，旨在控制以凝血受损或异常出血倾向为特征的病症。这些疾病，例如血友病、冯维勒布兰德病和血小板功能障碍，是由凝血因子、血小板或血管完整性的缺乏或缺陷引起的。治疗策略依具体疾病而有所不同，可能包括凝血因子替代疗法、抗纤维蛋白溶解剂、去氨加压素，在某些情况下还包括基因疗法。这些治疗旨在控制出血事件，预防关节损伤或器官出血等併发症，并提高受影响个体的整体生活品质。治疗方式的进步显着改善了结果，允许考虑疾病严重程度、患者年龄和生活方式因素的个人化方法。

市场动态

由于遗传易感性、人口老化和疾病意识提高等因素，全球出血性疾病的盛行率不断增加，有助于出血性疾病治疗市场的扩张。此外，治疗方案的进步，包括延长半衰期的凝血因子和基因编辑和 RNA 干扰等新型疗法，正在透过提供更有效、更方便的治疗方案来改变患者的照护。不断增长的医疗保健支出，尤其是在已开发经济体，支持了对创新疗法研发的投资。这些努力旨在提高治疗效果、减轻治疗负担、提高患者依从性。此外，透过合作伙伴关係和政府措施改善发展中地区获得治疗的机会正在扩大市场范围。此外，不断变化的监管环境简化了新疗法的审批流程并为罕见疾病治疗提供了激励，进一步刺激了市场成长。製药公司和研究机构之间的策略合作也推动创新并加速下一代出血性疾病疗法的开发。然而，某些地区高昂的治疗成本和有限的专业护理机会是市场成长的重大障碍。经济限制和昂贵疗法的报销挑战阻碍了采用率，特别是在发展中国家，从而限制了出血性疾病治疗市场的扩张。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球出血性疾病治疗市场的各个细分市场进行了包容性评估。出血性疾病治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

出血性疾病治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按类型分析

甲型血友病
乙型血友病
血管性血友病
其他的

按药物类别

血浆衍生凝血因子浓缩物
重组凝血因子浓缩物
去氨加压素
抗纤溶药
纤维蛋白密封剂
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲出血性疾病治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。出血性疾病治疗市场的主要参与者包括拜耳公司、CSL Behring、诺和诺德、辉瑞公司、Shire PLC、Grifols SA、Octapharma、安进公司、Cangene Corporation、Alnylam Pharmaceuticals。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：出血性疾病治疗公司的竞争格局

出血性疾病治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Bayer AG

公司概况
公司收入
产品
最新动态

CSL Behring

公司概况
公司收入
产品
最新动态

Novo Nordisk

公司概况
公司收入
产品
最新动态

Pfizer Inc.

公司概况
公司收入
产品
最新动态

Shire PLC

公司概况
公司收入
产品
最新动态

Grifols SA

公司概况
公司收入
产品
最新动态

Octapharma

公司概况
公司收入
产品
最新动态

Amgen Inc.

公司概况
公司收入
产品
最新动态

Cangene Corporation

公司概况
公司收入
产品
最新动态

Alnylam Pharmaceuticals

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112115274

The global demand for Bleeding Disorder Treatment Market is presumed to reach the market size of nearly USD 34.39 Billion by 2032 from USD 16.29 Billion in 2023 with a CAGR of 8.66% under the study period 2024-2032.

Bleeding disorder treatments encompass a range of therapeutic interventions aimed at managing conditions characterized by impaired blood clotting or abnormal bleeding tendencies. These disorders, such as hemophilia, von Willebrand disease, and platelet function disorders, result from deficiencies or defects in clotting factors, platelets, or blood vessel integrity. Treatment strategies vary based on the specific disorder and may include clotting factor replacement therapies, antifibrinolytics, desmopressin, and, in some cases, gene therapy. These treatments aim to control bleeding episodes, prevent complications like joint damage or organ bleeding, and improve the overall quality of life for affected individuals. Advances in treatment modalities have significantly enhanced outcomes, allowing for personalized approaches that consider disease severity, patient age, and lifestyle factors.

MARKET DYNAMICS

The increasing prevalence of bleeding disorders globally due to factors such as genetic predisposition, aging population, and improved disease awareness contribute to bleeding disorder treatments market expansion. Moreover, advancements in treatment options, including extended half-life clotting factors and novel therapies like gene editing and RNA interference, are transforming patient care by offering more effective and convenient treatment regimens. Rising healthcare expenditure, especially in developed economies, supports investment in research and development of innovative therapies. These efforts aim to improve treatment efficacy, reduce treatment burden, and enhance patient compliance. Additionally, initiatives to improve access to treatment in developing regions through partnerships and government initiatives are expanding market reach. Furthermore, evolving regulatory landscapes that streamline approval processes for new therapies and provide incentives for rare disease treatments further stimulate market growth. Strategic collaborations between pharmaceutical companies & research institutions also drive innovation & accelerate the development of next-generation therapies for bleeding disorders. However, high treatment costs and limited access to specialized care in certain regions are significant barriers to market growth. Economic constraints and reimbursement challenges for expensive therapies hinder adoption rates, particularly in developing countries, thereby restricting the expansion of the bleeding disorder treatment market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Bleeding Disorder Treatment. The growth and trends of Bleeding Disorder Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Bleeding Disorder Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type Analysis

Hemophilia A
Hemophilia B
Von Willebrand Disease
Others

By Drug Class

Plasma-Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytic
Fibrin Sealants
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Bleeding Disorder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Bleeding Disorder Treatment market include Bayer AG, CSL Behring, Novo Nordisk, Pfizer Inc., Shire PLC, Grifols SA, Octapharma, Amgen Inc., Cangene Corporation, Alnylam Pharmaceuticals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. BLEEDING DISORDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type Analysis
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL BLEEDING DISORDER TREATMENT MARKET ANALYSIS BY TYPE ANALYSIS

5.1. Overview By Type Analysis
5.2. Historical and Forecast Data Analysis By Type Analysis
5.3. Hemophilia A Historic and Forecast Sales By Regions
5.4. Hemophilia B Historic and Forecast Sales By Regions
5.5. Von Willebrand Disease Historic and Forecast Sales By Regions
5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL BLEEDING DISORDER TREATMENT MARKET ANALYSIS BY DRUG CLASS

6.1. Overview By Drug Class
6.2. Historical and Forecast Data Analysis By Drug Class
6.3. Plasma-Derived Coagulation Factor Concentrates Historic and Forecast Sales By Regions
6.4. Recombinant Coagulation Factor Concentrates Historic and Forecast Sales By Regions
6.5. Desmopressin Historic and Forecast Sales By Regions
6.6. Antifibrinolytic Historic and Forecast Sales By Regions
6.7. Fibrin Sealants Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL BLEEDING DISORDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE BLEEDING DISORDER TREATMENT COMPANIES

8.1. Bleeding Disorder Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF BLEEDING DISORDER TREATMENT INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Bayer AG
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. CSL Behring
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Novo Nordisk
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Pfizer Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Shire PLC
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Grifols SA
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Octapharma
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Amgen Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Cangene Corporation
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Alnylam Pharmaceuticals
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

简介目录图表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Type Analysis (USD MN)
Hemophilia A Market Sales By Geography (USD MN)
Hemophilia B Market Sales By Geography (USD MN)
Von Willebrand Disease Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By Drug Class (USD MN)
Plasma-Derived Coagulation Factor Concentrates Market Sales By Geography (USD MN)
Recombinant Coagulation Factor Concentrates Market Sales By Geography (USD MN)
Desmopressin Market Sales By Geography (USD MN)
Antifibrinolytic Market Sales By Geography (USD MN)
Fibrin Sealants Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Bleeding Disorder Treatment Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Bleeding Disorder Treatment Report
Market Research Process
Market Research Methodology
Global Bleeding Disorder Treatment Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Type Analysis
Market Attractiveness Analysis By Drug Class
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Type Analysis (USD MN)
Hemophilia A Market Sales By Geography (USD MN)
Hemophilia B Market Sales By Geography (USD MN)
Von Willebrand Disease Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By Drug Class (USD MN)
Plasma-Derived Coagulation Factor Concentrates Market Sales By Geography (USD MN)
Recombinant Coagulation Factor Concentrates Market Sales By Geography (USD MN)
Desmopressin Market Sales By Geography (USD MN)
Antifibrinolytic Market Sales By Geography (USD MN)
Fibrin Sealants Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis